11 recruiting. 11 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Recruiting 11 |
| Phase 2 | 2 | Recruiting 2 |
Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Recruiting | SystImmune Inc. | 520 | 2026-09-01 | 2026-10-13 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) Sacituzumab tirumotecan, Vinflunine, Docetaxel - Bladder Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 590 | 2026-04-23 | 2026-10-19 |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Dato-DXd, Carboplatin, Cisplatin - Urothelial Cancer, Bladder Cancer | Phase 2 / Phase 3 | Recruiting | Daiichi Sankyo | 630 | 2025-09-26 | 2026-08-20 |
| Trop2-targeted immunoPET Imaging of Solid Tumors [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4 - Solid Tumor, Solid Carcinoma | Phase 2 / Phase 3 | Recruiting | RenJi Hospital | 400 | 2024-12-23 | 2026-05-29 |
| Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection Cysview, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system - Bladder Cancer | Phase 3 | Recruiting | Johns Hopkins University | 200 | 2024-12-20 | 2025-11-18 |
| A Study of Surgical Techniques During Cystectomy Stent placement, Alvimopan - Bladder Cancer | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 530 | 2024-11-21 | 2026-09-22 |
| Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus Calmette-Guerin: Strain TICE - Bladder Cancer, Bladder Cancer Recurrent | Phase 3 | Recruiting | Verity Pharmaceuticals Inc. | 540 | 2024-04-24 | 2026-03-20 |
| The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial) Immunonutrition - Bladder Cancer, Interstitial Cystitis | Phase 3 | Recruiting | Centre Hospitalier Universitaire Vaudois | 232 | 2023-04-10 | 2025-12-09 |
| Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline) Gemcitabine Hydrochloride combined with continuous saline irrigation, Epirubicin Hydrochloride combined with continuous saline irrigation - Bladder Cancer | Phase 3 | Recruiting | University of Thessaly | 180 | 2021-12-14 | 2022-01-26 |
| Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) Gemcitabine, Cisplatin, Carboplatin - Bladder Cancer, Bladder Urothelial Carcinoma | Phase 3 | Recruiting | University Health Network, Toronto | 14 | 2021-02-08 | 2026-10-06 |
| Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol Alvimopan, Placebo - Bladder Cancer | Phase 3 | Recruiting | Brigham and Women's Hospital | 136 | 2018-10-01 | 2023-09-28 |
Urinary Bladder Neoplasms (11) · Carcinoma, Transitional Cell (2) · Cholangiocarcinoma (1) · Cystitis, Hemorrhagic (1) · Cystitis, Interstitial (1) · Endometrial Neoplasms (1) · Endometriosis (1) · Head and Neck Neoplasms (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Malnutrition (1) · Nasopharyngeal Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Male Urogenital Diseases (11) · Neoplasms by Site (11) · Urogenital Diseases (11) · Urogenital Neoplasms (11) · Urologic Diseases (11) · Urologic Neoplasms (11) · Neoplasms (10) · Urinary Bladder Diseases (10) · Pathological Conditions, Signs and Symptoms (3) · Carcinoma (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Neoplasms by Histologic Type (2)
Carboplatin (3) · Cisplatin (3) · Gemcitabine (3) · alvimopan (2) · 5-aminolevulinic acid hexyl ester (1) · BCG Vaccine (1) · Docetaxel (1) · Drug Delivery Systems (1) · Drug Therapy (1) · Immunonutrition Diet (1) · Paclitaxel (1) · Platinum Compounds (1) · vinflunine (1)
Brigham and Women's Hospital (1) · Centre Hospitalier Universitaire Vaudois (1) · Daiichi Sankyo (1) · Johns Hopkins University (1) · Memorial Sloan Kettering Cancer Center (1) · Merck Sharp & Dohme LLC (1) · RenJi Hospital (1) · SystImmune Inc. (1) · University Health Network, Toronto (1) · University of Thessaly (1) · Verity Pharmaceuticals Inc. (1)
United States (6) · Canada (3) · China (3) · France (2) · Germany (2) · Greece (2) · Italy (2) · Japan (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Israel (1) · Netherlands (1)
Alexandre R Zlotta, MD, PhD, FRCSC (1) · Alvin Goh, MD (1) · Armine Smith, MD (1) · Girish Kulkarni, MD (1) · Girish S Kulkarni, MD (1) · Jianjun Liu, Ph.D. & M.D. (1) · Jimmy Liu Zhao, MD, PhD (1) · Mark A Preston, MD (1) · Vasileios Tzortzis, Professor (1) · Weijun Wei, Ph.D. & M.D. (1)